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Superior vena cava replacement for
lung cancer using a heterologous
(bovine) prosthesis: Preliminary
results
To the Editor:
We read with great interest the article by
Spaggiari and associates,1 and we congrat-
ulate the authors for their original contri-
bution.
In agreement with the authors, we think
that the use of a synthetic (polytetrafluoro-
ethylene) prosthesis is burdened by several
problems, but we disagree with their state-
ment that the autologous pericardium is not
sufficient to create a long enough tube to
replace the superior vena cava (SVC) com-
pletely or in the majority of its length.
In our experience, we used fresh autol-
ogous pericardium to replace the SVC
(Figure 1, a) in a small series of patients
who had a good short- and long-term out-
come. In fact, the autologous pericardium
can be easily obtained from the patient and
it can be shaped by a technique similar to
that reported by Spaggiari’s group. Lung
tumor primarily invading the SVC is the
best indication for surgery; we exclude
from surgery patients with SVC involve-
ment by N2 disease. The primary lung tu-
mor usually infiltrates only the anterolat-
eral and posterolateral walls of the SVC.
Therefore, the indication for complete SVC
replacement is very limited, because it is
often possible to apply a pericardial patch.
Usually, a complete replacement of the
SVC is considered mandatory for tumor
invading more than 50% of the vascular
wall. Nevertheless, in some cases in our
experience we avoided total SVC replace-
ment by using a large autologous fresh
pericardial patch shaped to cover up to two
thirds of the SVC circumference (Figure 1,
b ), without resorting to glutaraldehyde-
preserved pericardial patches, as described
by other authors.2
In conclusion, on the basis of our expe-
rience, we favor the use of autologous ma-
terial to reduce the potential risks related to
the application of heterologous prostheses,
even if adequately pretreated.
In most cases, an angioplasty with a
well-shaped autologous pericardial patch
can be used to cover the vascular defect.1-2
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Intraoperative indocyanine green
angiography: Ready for prime time?
To the Editor:
We read with interest the report by Desai and
associates1 comparing intraoperative graft
evaluation using indocyanine green (ICG)
angiography and transit-time ultrasound flow
(TTF) measurements. Our group also shared
in the enthusiasm for ICG angiography when
it was introduced,2 and we congratulate the
authors on their efforts to validate this novel
technology as a quality improvement initia-
tive in coronary surgery.3 In our opinion,
maximizing coronary artery bypass graft
patency is a highly relevant issue.
In our experience, we found an impor-
tant learning curve with ICG angiography,
and we noted difficulty in the assessment of
coronary anastomoses involving arterial
pedicles, such as nonskeletonized internal
thoracic artery (ITA) and radial artery grafts.
We routinely skeletonized the distal portion
of arterial grafts, and yet the images created
by ICG angiography were still unclear at the
anastomotic level. We would be interested to
learn of the authors’ experience with the
evaluation of ITA grafts using ICG angiog-
raphy and whether they now skeletonize their
ITA grafts for this purpose. Another issue
that was not addressed in this study relates to
ICG costs, including the capital investment
necessary to acquire the imaging device and
the per-case costs. Can the authors comment
on the cost effectiveness of the two tech-
niques for the intraoperative assessment of
graft patency?
More important, however, we are con-
cerned with the analysis of sensitivity and
specificity in Desai and colleagues’ article.
In the evaluation of sensitivity and speci-
ficity of a new diagnostic test, the validity
of the analysis is intimately dependent on
the definitions chosen for “positives” and
“negatives.” We disagree with the defini-
tion of “normal” used by the authors for
TTF assessment, and we could not find any
previous studies to support the authors’ use
of greater than 10 mL/min as a cutoff for
“normal.” Applying the definitions of De-
sai and associates, a vein graft to a large
obtuse marginal coronary artery with high-
grade proximal stenosis measured to have a
pulsatility index of 4.9, diastolic flow frac-
tion of 60%, and mean flow of 12 mL/min
would be considered “normal.” In our
view, such a graft is abnormal because flow
would be expected to be much higher than
Figure 1. a, Complete replacement of SVC
with a long tube constructed of autolo-
gous pericardium. b, Autologous pericar-
dial patch applied to cover a large vascu-
lar defect after partial SVC resection.
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